The drug, marketed under the brand name Tzield and based on the active antibody teplizumab, has shown promising results in clinical trials. It is designed to intervene in the disease's progression ...

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Sanofi has agreed a deal to buy US biopharma company Provention Bio for $2.9 billion, taking control of a recently-approved type 1 diabetes (T1D) prevention therapy Tzield that has been tipped as ...

Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced ...

Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, ...

Pero hay un inconveniente. En sus primeras etapas, la diabetes no causa síntomas, pero el medicamento, comercializado como Tzield, solo es efectivo durante esta fase silenciosa. Esta es la ...

CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the ...